Study of HB0017 for people with plaque psoriasis
Part of Skin clinical trials.
This trial tests an investigational drug, HB0017, in adults with moderate to severe plaque psoriasis. If you have had psoriasis for at least 6 months and have not used certain biologic treatments, you may be able to join.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old
- You have had plaque psoriasis for at least 6 months
- Your psoriasis covers at least 10% of your body surface area and is moderate to severe
- You have not previously taken a drug that targets IL-17 or its receptor
- You have not used certain biologic treatments within specific time frames before joining
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an oral tablet (CMS-D001) for adults with moderate to severe plaque psoriasis. It aims to see if the drug is safe and effective in reducing psoriasis severity.
This trial tests a new medication called HB0017 for moderate to severe plaque psoriasis. It aims to see if it is safe and effective in reducing skin symptoms and improving quality of life.
This trial tests a new drug called HS-20137 for people with moderate to severe plaque psoriasis. It might help reduce skin symptoms like redness, scaling, and itching.
This study tests an investigational oral medication called HS-10374 for moderate to severe plaque psoriasis. It aims to see how well it clears skin and prevents flares compared to a placebo, and if it is safe for long-term use.
This trial tests an oral medication called HS-10374 for people with mild to moderate plaque psoriasis who haven't gotten enough relief from topical treatments. The study will check if the drug is safe and effective at clearing psoriasis patches.
This study tests a new injectable medicine for people with moderate-to-severe plaque psoriasis. It aims to see if it is safe and effective at reducing symptoms like redness and scaling.
Hear when a new Psoriasis (PsO) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.